International NET COVID-19 Survey Published in Journal of Neuroendocrinology

Prof. Marianne Pavel is the Chair of Endocrinology at the Department of Medicine 1, University of Erlangen, Germany. Board certified as a specialist in internal medicine in 2000 and endocrinology/diabetes in 2001; she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position as an Assistant Director at the Charité University Hospital, Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité University in 2010. In 2009, under her guidance, the NET Center at the Charité University was certified as one of the first ENETS Centers of Excellence. Her major focus in medicine is neuroendocrine tumors for more than 20 years. She has conducted numerous clinical trials in the field of NET. She is involved in the activities from ENETS since 2005 and is first author of the 2012 and the updated 2016 “ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary”. Since April 2014 she is a member of the Executive Committee of ENETS and has recently been elected as chair of ENETS up from 2020. She is involved in scientific and educational activities in NET from different societies including German Cancer Foundation and ESMO.

Prof. Martyn Caplin is Professor of Gastroenterology & GI Neuroendocrinology at the Royal Free Hospital and University College London. He leads The Royal Free Hospital’s “European Neuroendocrine Tumour Society’s Centre of Excellence”. Furthermore, he leads scientific and clinical research programmes into neuroendocrine tumours. In addition to being the Chairman ENETS (2014-2016), he now serves on its advisory board. He has been with ENETS since its foundation in 2004. He received a Lifetime Achievement Award from the UK & Ireland Neuroendocrine Tumour Society (UKI NETS) in recognition of his clinical leadership and research in the field of NETs. He is a founder and Past-Chairman of the UK & Ireland Neuroendocrine Tumour Society. 2006-2014 he was a member of the National Cancer Research Institute (NCRI) Upper-G.I. Cancer Committee and he is a Past-Chairman of the NCRI Neuroendocrine Tumour group. He is a Patron of the NET Patient Foundation. He has published over 200 peer-reviewed papers, written multiple book chapters and co-authored two books. He regularly lectures both nationally and internationally. 2006-2012 he was the clinical lead for “NHS Evidence” for Gastroenterology and Liver diseases (under the auspices of NICE), chairing annual evidence updates into gastrointestinal and liver disorders.

Prof. Martyn Caplin has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Chiasma, Novartis, Ipsen and Pfizer. 

Dr Jorge Hernando is a Medical Oncologist at Vall d´Hebron University Hospital in Barelona, Spain. Jorge obtained his MD degree in 2010, and the Specialty in Medical Oncology in 2016 at the Miguel Servet University Hospital in Zaragoza, Spain. In 2017 he obtained his PhD and joined the Gastrointestinal and Endocrine Tumor Unit at Vall d´Hebron University Hospital. He is mainly committed to the clinical management of patients affected by gastrointestinal, neuroendocrine and endocrine malignancies. Jorge is involved in clinical and translational research projects at the Vall d´Hebron Institute of Oncology (VHIO) and he is also coordinator of the gastrointestinal and neuroendorine patient advocacy group. Dr Hernando is involved in professional societies including the American Society of Clinical Oncology (ASCO), European Society for Medical Onology (ESMO), European Neuroendocrine Tumor Society (ENETS) and Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).

Dr Mauro Cives works as Assistant Professor of Medical Oncology in the Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. He gained his MD degree and specialization degree in Medical Oncology at the University of Bari. From 2013 to 2016 Dr Cives worked as Research Associate within the Neuroendocrine Program of the Moffitt Cancer Center & Research Institute, Tampa (FL, USA). Dr Cives’ work focuses on the preclinical and clinical evaluation of innovative treatments for neuroendocrine tumors (NETs). In 2017, Dr Cives was awarded by the European Neuroendocrine Tumor Society (ENETS) for the project “CAR-T cells for GEP-NETs”. Dr Cives is co-author of over 30 peer-reviewed papers.

Asst. Prof. Mauro Cives has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA and Ipsen. 

Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.

Dr Angela Lamarca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, EISAI, Merck, Mylan and Delcath, Novartis, Nutricia, Roche, SrtEx and QED.